Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in CALGB 51101 (Alliance) Batchelor, T , Giri, S , Stark, A , Bartlett, N , Hsi, E , Cheson, B ... - ASCO - J Clin Oncol. - 2020 Abstract - Primary - Primary - Lymphoma - CALGB-51101
Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy Harzstark, A. L. , Halabi, S. , Kelly, W. K. , Morris, M. J. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401
Hypertension is associated with clinical outcome for patients (Pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206 Harzstark, A. L. , Halabi, S. , Stadler, W. M. , Vaena, D. A. ... - ASCO GU - Genitourinary Cancers Symposium - 2010 Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206
Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials Jones, J. A. , Stark, A. , Zhao, W. , Lin, T. S. , Rai, K. R. ... - - Blood - 2011 Abstract - Secondary-not-in-original - Comprehensive - Leukemia - CALGB-10101 , CALGB-19901
Treatment with fludarabine and rituximab produces extended remissions and survival in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: Long-term follow up of CALGB study 9712 Woyach, J. , Heerema, N. A. , Stark, A. , Peterson, B. L. ... - - Blood - 2009 Abstract - Primary - Primary - Leukemia - CALGB-9712
